CD3 and CD4+ cells were lower in all treatment groups than in the control group, CD3 were significantly lower in the high ASMq dose and 2 g/kg ASMq groups than in the untreated cancer model (p <0.05), a pattern also reproduced for CD4 cells, though not significantly. This evidence concerns the gene CD4 and cancer.